Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention
Our results suggest that heterogeneity in risk was the most important source of efficacy dilution in the ASPIRE trial. Future trials of HIV-1 prevention products for women should consider alternative trial designs and analytic approaches that minimize bias introduced by heterogeneity in risk.
Authors
- Kathryn Peebles
- Laura Matrajt (ORCID: https://orcid.org/0000-0003-4495-7245)
- Jared M. Baeten (ORCID: https://orcid.org/0000-0001-8242-8438)
- Elizabeth R. Brown (ORCID: https://orcid.org/0000-0003-4286-2111)
- Thesla Palanee-Phillips
Institutions
- University of the Witwatersrand (ZA)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- University of Washington Applied Physics Laboratory (US)
Publication Details
- Journal
- International Journal of STD & AIDS
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1177/09564624241300199
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development